MAP2K4 and cancer: Interestingly, we found three mutations, EGFR L861Q, MAP2K4 S184L, and TP53 E285V, that were PCMs in TCGA but became SPMs in MSK-IMPACT tumors, suggesting that cancer-specific selection may drive them during the continuous progression of related tumors.